thyme buy initi outperform
initi coverag outperform rate pt base
view becom leader anti-depress two drug
late-stag develop iv brexanolon postpartum depress oral
major depress disord mdd three near-term catalyst
could unlock signific valu especi key contributor
valuat view catalyst skew toward posit outcom
brexanolon well posit upcom ad pdufa
opinion base favor risk/benefit ratio indic fda-
approv therapi data on-going trial
develop compound target gaba nmda receptor system
regul nerv signal brain focu depress brexanolon
iv formul synthet allopregnanolon lead asset
develop oral once-daili alloster modul
gaba-a develop mdd
brexanolon well posit upcom ad pdufa
opinion like get approv base favor risk/benefit
profil indic approv therapi compound posit data
two trial manag side effect compar current
data on-going trial anoth potenti
catalyst simultan studi mdd
compound show strong proof-of-concept data mdd see
posit read-across data posit data
brexanolon also modul gaba
assum brexanolon launch net price estim
po peak unrisk-adjust us sale row
forecast launch net price po peak
unrisk-adjust sale mdd
valu use dcf analysi assum wacc
residu growth rate assum loss ip protect off-set
addit pipelin asset cash balanc see
compani well posit ahead major catalyst year-end could
therapeut clinical-stag
develop novel medicin
transform live patient life-
analyst certif import disclosur see disclosur
brexanalon receiv fda approv decemb
launch
progress mdd
outperform rate base view compani
leader disord especi depress two major
drug develop brexanolon postpartum depress
major depress disord mdd
compound alloster modul gaba receptor offer
new mechan action treat depress could address
initi trial pd
adcomm brexanolon
receipt ema scientif advic brexanolon
data
initi mdd trial
data competitor top-line data moder
brexanolon approv eu
open-label lte trial requir file
brexanolon fail get approv us
schedul sever
valu use dcf analysi assum wacc residu growth rate due loss ip protect
addit pipelin asset unrisk-adjust ww sale estim asset brexanolon risk-adjust
risk-adjust model probabl success brexanolon mdd
key downsid risk price target clinic develop risk regulatori risk brexanolon addit risk come lower
expect peak sale due higher anticip competit failur gain support medic commun healthcar prescrib
third-parti payor risk relat legal challeng patent protect product
tabl content
initi coverag inc outperform rate
price target base view compani leader disord
especi depress two major drug develop iv brexanolon
postpartum depress oral major depress
disord mdd compound alloster modul gaba receptor
offer new mechan action treat depress addit develop
compound insomnia bipolar depress parkinson diseas essenti tumor
epileptiform disord nmda hypofunct
three upcom catalyst year-end could unlock substanti valu especi
base data key contributor estim valuat
brexanolon well posit upcom fda advisori committe
meet nov pdufa date dec opinion like get
approv base risk/benefit ratio indic fda-approv
therapi compound posit data two trial manag
side effect compar current treatment option
data on-going trial like posit
catalyst view simultan studi mdd
subset mdd compound show strong proof-of-
concept data mdd expect posit read-through
see larg viabl market opportun despit forecast
sale fall consensu base view potenti payor
pressur front-lin mdd set gener domin
un-risk-adjust world-wide sale estim asset brexanolon
risk-adjust risk-adjust model
probabl success po brexanolon po
mdd cash balanc fund oper
accord manag
valu use dcf analysi assum wacc
residu growth rate assum loss ip protect off-set addit
pipelin asset sage cash balanc fund oper
estim least women us year
eu may experi incid new mother model
moder sever symptom assum brexanolon launch post
decemb pdufa date model po peak ms model price
net price per cours therapi premium brand
antidepress use off-label indic assum row
launch without eu assum ms lost easier
oral administr efficaci compar estim peak risk un-adjust us sale
row assum po
model potenti launch net price per cours therapi
us base pariti brand antidepress gross
sale net sale discount half us price eu row assum
peak market share could reach two-third patient moderate-sever symptom
risk un-adjust us sale forecast row po
estim risk-adjust us sale estim
row mdd set model primari use
ssri treatment-resist set despit posit compound
compani base view reimburs landscap project
potenti approv model potenti penetr mdd
patient expect risk un-adjust ww peak sale reach mdd
us row assum po model us
row risk-adjust peak revenu mdd ww risk-
face sever major catalyst year-end brexanolon pdufa date
set decemb associ ad novemb
pivot top-lin data expect addit initi
mdd anoth catalyst
time calendar fiscal asset trial ivreceipt ema scientif advic addit placebo-control efficaci studi placebo-control data ppdnov ivadcomm ppddec initi bipolar depress sleep trial mdd bipoalr depress pd sleep ivpotenti commerci launch ppdsourc oppenheim co estim compani inform outperform
key downsid risk price target clinic develop risk regulatori risk
brexanolon addit risk come lower expect peak
sale due higher anticip competit failur gain support
medic commun healthcar prescrib third-parti payor risk relat
legal challeng patent protect product
histori stock price
inc cambridg ma-bas biopharmaceut compani
focus develop therapi disord especi depress compani
proprietari compound develop target gaba nmda receptor
system regul nerv signal brain
brexanolon compani lead asset inject proprietari formul
allopregnanolon brexanolon design address studi show
allopregnanolon posit alloster modul gaba-a receptor level
allopregnanolon found lower women healthi women two
succesful trial brexanolon shown efficaci addit
develop oral activ formul allopregnanolon use
mechan action moa compound current data
expect
also focus develop treatment patient mdd
oral daili alloster modul gaba-a receptor act
inhibitori synaps brain anxieti depress symptom mdd
studi patient mdd show statist signific reduct
ham-d score versu placebo day well toler grant
breakthrough therapi design fda februari announc
expedit develop plan us singl addit pivot
control trial patient mdd expect initi
expect peak sale brexanolon reach ww
brexanolon un-risk-adjust assum
probabl success brexanolon probabl success
expect brexanolon potenti approv
expect peak sale mdd reach ww us un-
risk-adjust market share mdd patient initi annual net
price per cours therapi us assum probabl success
mdd un-risk-adjust ww sale asset brexanolon risk-
adjust risk-adjust
revenuesmillion usdunadj brexanolon salesunadj revenuesmillion usdrisk-adj brexanolon salesrisk-adj salesbrexanolon po po -brexanolon un risk-adjust revenuestot brexanolon total mddbrexanolon risk-adjust revenuestot brexanolon total mdd therapeut
brexanolon postpartum depress
postpartum depress complic childbirth character signific
depress symptom affect women give birth global
estim women us year may experi
moder sever symptom childbirth level estrogen
progesteron hormon quickli drop lead chemic chang brain may
lead symptom common symptom includ depress mood anxieti
agit chang eat sleep habit fatigu decreas energi inabl
concentr symptom typic start third trimest pregnanc
month follow childbirth symptom broad may vari women
healthcar provid help woman figur whether symptom due
optim time screen two week six month
deliveri psychotherapi may use mild-moder sever first-lin therapi
second-lin therapi pharmacotherapi fda-approv drug treat
current pharmacolog treatment target sever moa
pharmacolog therapi approv antidepress use design
enhanc function serotonin norepinephrin zoloft typic first choic due
product profil allow breastfeed zoloft report minim
effect central serotonin transport infant drug take week
month develop antidepress action therefor urgent medic need
novel faster-act antidepress
exhibit symptom
increas evid point associ decreas gamma-
gaba receptor gaba main function reduc neuron excit
act inhibitori synaps brain upon bind gaba-a receptor
open cl channel allow chlorid ion neuron make cell hyperpolar
less like fire posit alloster modul gaba-a increas effect
gaba make channel open frequent longer period posit
alloster modul bind activ site gaba neurotransmitt
molecul affect receptor bind differ site protein besid
nervou system gaba also produc cell pancrea intestin uteru
ovari peripher tissu lower level two gener class
gaba receptor ionotrop gaba-a metabotrop gaba-b receptor gaba-a
receptor part ligand gate ion channel complex open ion
channel allow flow chlorid ion cell potassium ion cell
gaba-b receptor protein-coupl receptor open close via protein
intermediari gaba-a receptor target protein compos five subunit
chlorid cl- ion channel pore two gaba activ bind site interfac
benzodiazepin bzd alloster bind site interfac alloster
modul gaba-a receptor enhanc inhibitori effect gaba reduc
anxieti depress panic disord exampl modul
allopregnanolon posit alloster modul gaba-a receptor level
lower women healthi women natur occur allopregnanolon
found highest level women third trimest pregnanc return
normal level within hour give birth develop inject proprietari
formul allopregnanolon brexanolon natur occur neuroact steroid
act posit modul gaba-a receptor
clinic data
studi conduct femal sever hamilton depress
rate scale ham-d score prior random trial
moder ham-d score prior random
trial hummingbird random trial three treatment group
brexanolon g/kg/hour brexanolon g/kg/hour placebo basi
sever pdd patient hummingbird random trial two treatment
group brexanolon g/kg/hour placebo basi moder patient
brexanolon administ hour via iv infus primari endpoint
measur signific reduct baselin ham-d hour compar
sever result g/kg/hour dose show statist signific
mean reduct ham-d bl versu mean reduct placebo group
 valu point placebo correct reduct ci
g/kg/hour dose group also achiev statist signific greater result
mean reduct ham-d bl versu mean reduct placebo
valu point placebo correct reduct ci effect
observ hour brexanolon group maintain day follow
improv cgi-i scale hour consist primari endpoint
g/kg/hour g/kg/hour dose
moder result g/kg/hour dose show statist
signific mean reduct ham-d score bl hour valu
versu point mean reduct ham-d placebo point placebo
correct reduct ci consid line result
hummingbird improv cgi-i scale hour consist
primari endpoint valu
onset durat efficaci trial statist signific first
respons observ hour dose remain throughout day sever
patient effect remain statist signific day moder
patient due improv placebo arm trial
safeti trial patient experienc sae over-sed syncop resolv
without addit treatment upon cessat brexanolon infus howev neither
requir hospit classifi relat studi drug common
headach dizzi somnol
common treatment-emerg brexanolon group headach
group group vs placebo group studi
group vs placebo group sever dizzi group
group vs placebo group studi group vs placebo group
moder somnol group group vs
placebo group studi group vs placebo group
moder sever one patient group two seriou
suicid ideat intent overdos attempt follow-up
moder one patient group two seriou advers event alter
state conscious syncop consid treatment-rel
exhibit hummingbird sever moder
exhibit hummingbird sever studi moder
studi durat efficaci stat sig maintain day dose
sever patient hummingbird moder patient due
studi descriptiontreat descriptionplacebobrexanolon reduct baselin pointstot score hour primari endpoint p-valu vs improv cgi-iat endpoint p-valu vs hummingbird studi sever hummingbird studi moder therapeut
exhibit hummingbird sever studi moder
brexanolonepotenti import
treatment option sever
mani older antidepress commonli use off-label may take week
notic effect approxim one-third patient respond sever dose
adjust may requir patient reach peak efficaci drug
typic taken month year avoid relaps newer antidepress lexapro
prozac zoloft small trace show breast milk like caus
harm effect newborn cardiac cranial defect meta-analysi ssri
show respons remiss rate favor ssri placebo
exhibit meta-analysi ssri show ssri repres valid
respons remiss rate
demonstr efficaci two ssri paroxetin sertralin
women suffer
de crescenzo et al aff disord
anoth altern ketamin infus therapi ketamin off-label intraven usag
may recommend provid sever case total six infus may
provid mani month relief without side effect associ
antidepress brexanolon one-tim iv provid reduct ham-d
level similar ketamin effect last far longer
observ withdraw symptom rebound effect date
competitor clinic develop also target gaba-a receptor marinu
pharmaceut inc ganaxolon lead product candid
similar brexanolon ganaxolon synthet analog endogen
allopregnanolon design ad methyl group bind gaba
synapt extrasynapt bind site studi done gaba inhibit show
increas tonic current observ exposur ganaxolon tonic current produc
gaba-a receptor activ gaba marinu run two phase studi
ganaxolon one oral formul top-line result expect
one iv formul top-line result expect clinic trial
random doubl blind placebo control studi evalu safeti toler
efficaci ganaxolon major primari endpoint measur ganaxolon
oral columbia suicid sever rate scale cssr day secondari
endpoint hamd assess day major primari endpoint measur
ganaxolon iv hamd cssr day marinu previous announc may
extens clinic trial review studi data compound similar
moa brexanolon second part trial patient receiv iv ganaxolon
variou infus length follow oral ganaxolon estim studi complement
late announc result decreas share
increas sage stock price
oral option may address competit advantag marinu
may oral drug marinu may push back timelin stay
competit increas enrol due strength brexanolon
exhibit brexanolon ganaxolon synapt extrasynapt
brexanolon posit
expect use brexanolon sever case especi in-pati set
brexanolon shown strong efficaci compar altern ssri etc
clean safeti profil key differenti fast onset action may import
sever brexanolon well posit first fda-approv therapi
howev ssri avail gener still provid efficaci albeit less
brexanolon addit two option horizon oral
ganaxolon
exhibit brexanolon posit strongest efficaci date could lead
best-in-class statu howev ssri gener oral compound
horizon poc data
submit brexanolon new drug applic nda treatment
fda may nda grant prioriti review statu fda
assign pdufa target date decemb prior pdufa date fda
ad held discuss brexanolon applic novemb
hold issu pend patent applic unit state brexanolon
us foreign patent applic cover proprietari formul brexanolon use
formul treat variou disord includ addit patent
applic cover certain aspect brexanolon includ cours treatment dosag
regimen method manufactur brexanolon iv one issu us patent cover
composit matter expir april pend us foreign patent
applic cover use treat variou disord solid form
provid assur pend patent
applic matur issu patent patent enforc
includ claim suffici protect product candid provid competit advantag
enter exclus licens agreement
own subsidiari ligand use captisol technolog develop
brexanolon treatment prevent diagnosi oblig pay
cydex certain clinical/regulatori mileston approv market single-digit
royalti brexanolon also enter suppli agreement cydex
sage commerci strategi five point
first goal commerci strategi awar sinc highli
healthcar strategi tri prepar hospit supervis home
set give mother option continu infus would allow
mother togeth infant administr still subject discuss
fda final label
payer negoti sinc april engag uniqu payer
interact share inform product profil relat current ssri
ci g/kg/hour ci g/kg/hour ci g/kg/hour day sever ppdday moder ham-d total score ssri vs listen sertralin vs paroxetin vs placeboremiss ham-d score vs placebohummingbird sertralin vs vs placebohummingbird paroxetin vs placebo outperform
treatment manag state take six month certain payer
certain hospit system get formulari reimburs
patient support oper high-touch case manag model patient
help patient navig treatment process brexalon go
site-of-car perspect program also engag healthcar provid provid
detail educ brexalon treatment
salesforc hire subset sale forc key account manag
focu hospit rest sale forc specialti sale rep
focu outpati set ob-gyn psychiatrist
eu expans evalu market plan stage
model incid case pdd annual us eu
assum case moder sever women seek
treatment lead address popul us eu
assum brexanolon launch post decemb pdufa model po
peak ms model price premium brand
antidepress use off-label indic assum row
launch without eu assum ms lost upon launch
easier oral administr efficaci compar us sale peg
row
postpartum depress
develop oral once-daili formul allopregnanolon
natur occur neuroact steroid act posit modul gaba-a
receptor mechan action ident brexanolon iv
current studi studi target enrol women age
year sever on-going multi-cent double-blind placebo-control
random clinic trial evalu two week treatment compar
placebo patient sever trial upsiz design pivot
follow result previous complet placebo-control studi
mdd announc decemb primari endpoint assess chang
baselin ham-d total score day secondari endpoint safeti toler
compar placebo assess day top-lin result anticip
model incid case pdd annual us eu
assum case moder sever women seek
treatment lead address popul us eu
model potenti launch net price per cours therapi
us base pariti brand antidepress discount
half us price eu row assum peak market share could
reach two-third patient moderate-sever symptom risk un-adjust us
sale row accord estim po
risk-adjust us sale estim row
major depress disord mdd depress disord caus persist
feel sad loss interest estim million peopl us
experi least one major depress episod per year sever
impair depress often begin teen happen
age estim peopl mdd receiv treatment health
profession take medic peopl mdd typic multipl episod
symptom sad empti irrit loss interest sleep disturb lack
energi reduc appetit anxieti slow think recurr thought death
mani depress symptom may sever enough caus problem day-to-day
activ exact caus depress mani factor may involv
biolog differ brain chemistri hormon inherit trait factor may
increas risk develop depress includ person trait stress event
bipolar disord experienc unsupport situat abus alcohol recreat
drug chronic ill current treatment depress includ therapi medic
lifestyl chang psychotherapi includ cognit behavior family-focus
interperson therapi medic includ antidepress mood stabil
antipsychot medic popular medic use depress today
cymbalta zoloft lexapro bupropion prozac mani other antidepress
avail either tricycl antidepress tca select serotonin
norepinephrin reuptak inhibitor antidepress ssnri select serotonin
reuptak inhibitor ssri tca market longest ssri
ssnri second gener antidepress difficult predict well particular
medic help individu therefor patient may take sever differ form
still symptom sever differ medic medic
effect within one two week may take longer symptom improv typic
taken one two year sometim longer prevent relaps side
effect associ drug increas likelihood diarrhea headach sleep
problem nausea ssri vs tricycl antidepress tca like
ssri caus vision problem constip dizzi dri mouth trembl
urin problem sever problem dizzi unsteadi feet increas risk
fall broken bone may also occur pubm
exhibit preval mdd treatment receiv among us adult
major depress
oral gaba receptor alloster modul mdd rapid onset
action high efficaci clean safeti profil signific receiv
breakthrough therapi design fda februari announc
expedit develop plan requir one addit pivot
control trial patient mdd expect initi open-label
episod treatment studi month year follow-up
mdd patient us typic treat combin counsel
antidepress current avail antidepress often ineffect measur
respons reduct symptom remiss larg prospect
random trial determin optim treatment mdd level treatment
patient experienc inadequ respons mdd patient
screen enrol trial cost year remiss
rate rang first two level therapi third
fourth level cumul remiss rate four level
mdd lead posit alloster modul gaba-a receptor
enhanc current elicit gaba allow stronger inhibitori effect neuron
act inhibitori synaps brain anxieti depress symptom
mdd
releas data multicent random double-blind placebo-control
trial societi biolog psychiatri sobp annual meet may
total patient male femal age unipolar depress ham-d
score baselin ham-d score balanc random
receiv capsul placebo day first day drug
administr inpati pk ae safeti measur obtain
day primari endpoint reduct ham-d versu placebo day madr
ham-a cgi-i also examin
show significantli greater mean reduct bl ham-d total
score day vs placebo valu onset activ
rapid statist signific improv ham-d score first observ day
maintain throughout day day
durabl statist signific week remain
numer superior placebo addit signific improv observ
madr ham-a cgi-i versu placebo seriou report
common group headach nausea dizzi
somnol overal placebo-control trial support
develop mdd
follow data conduct meet conclud fda
agre would qualifi one two requir pivot trial initi
yet enrol mdd studi recent placebo-control studi enrol
approxim patient moder sever mdd ham-d score
arm studi evalu dose compar placebo
primari endpoint evalu compar placebo day follow
week treatment follow day safeti secondari endpoint
similar design take success build larger scale studi
may show similar level clinic success
sever treatment option exist
exist treatment option mdd larg involv antidepress ssri snri
mani gener earli success new class antidepress
attract multipl entrant limit differenti featur addit indic
slightli differ side effect profil becam point differenti ssri
drug start lose patent protect multipl snri enter market
total market expans ssri snri antidepress driven new indic
variou mood anxieti disord new entrant ssri/snri market
offer improv efficaci instead focus improv toler new indic
result antidepress market dynam becam highli fraction across
multipl me-too therapi option character high rate switch among
past larg studi done fluoxetin patient venlafaxin ir
patient venlafaxin er patient assess week treatment
mdd overal adult geriatr patient show greater improv
antidepress compar placebo estim respons rate
antidepress compar placebo remiss rate ham-d score
less antidepress placebo statist signific
top-lin result mdd show stat sig mean point reduct ham-
score compar placebo point decreas day begin
one dose maint week secondari endpoint day includ
remiss treatment group versu placebo
exhibit ham-d respons ham-d remiss rate open-label trial
respond defin chang ham-d total score trial estim remiss rate
post day respons rate ssri estim respons rate
antidepress compar placebo remiss rate ham-d score less
antidepress placebo larg control ssri trial
new approach mdd focu
alkerm lead product oral k-opioid receptor kor antagonist use
adjunct treatment major depress disord mdd patient
inadequ respons current antidepress treatment activ kor induc
dysphoria stress-lik respons thought link depress anxieti drug
addict stress relat abnorm studi fail forward due
high placebo respons rate forward miss primari endpoint forward
posit high dose arm sublingu
samidorphan show statist signific reduct montgomery-
sberg depress rate scale score well
score lower arm fail achiev statist signific month
patient remit median time remiss day accord
result enrol patient complet studi discontinu due
advers event compani resubmit nda fda april refus
file letter due insuffici data review applic accept april
pdufa date set januari
johnson johnson esketamin intranas gener anesthet enantiom
ketamin act nmda receptor agonist nmda receptor class
glutamate-g cation channel bind glutam co-agonist allow influx
efflux posit charg ion na studi show block
nmda antidepress effect report result studi two
posit two narrowli miss statist signific show posit
trend lt studi fda grant esketamin breakthrough therapi
design treatment-resist depress failur two previou ssri
second indic mdd immin risk suicid nda submit fda
treatment-resist mdd submit ema later year
dr carlo zarat nimh colleagu publish landmark studi jama
psychiatri show ketamin provid robust efficaci within two hour patient
suffer treatment resist depress
allergan intraven nmda receptor agonist mdd rapastinel
serv alloster modul glycin site nmda receptor show evid
antidepress effect rapastinel receiv track breakthrough design
adjunct therapi treatment-resist mdd trial random double-
blind placebo-control multicent studi rapastinel adjunct therapi mdd
top-lin result expect
posit mdd may
mdd posit first-lin treatment compet gener
ssri base superior efficaci newer approach mdd focu
treatment resist popul antidepress failur mean enter market
plan expand exampl esketamin rapastinel
studi treatment-resist set reason select smaller
popul within mdd unmet need better negoti point payor
focus set may commerci risk despit unmet need
creat low respons rate antidepress payor
aggress compani extens experi struggl recent
launch brand antidepress trintellix vortioxetin takeda/lundbeck
viibryd vilazodon fetzima levomilnacipran
exhibit estim us sale three recent launch brand ssri trintellix takeda/lundbeck viibryd
fetzima payor aggress compani extens experi
struggl recent launch brand antidepress focus set may commerci
risk despit unmet need creat low respons rate antidepress
model lower sale vs consensu base analysi recent
launch mdd believ face payor pressur uptak
treatment resist popul
exhibit oppenheim vs consensu sale estim model lower sale vs
consensu base analysi recent launch mdd believ face payor
pressur uptak treatment resist popul
shionogi announc strateg collabor clinic develop
commerci treatment mdd indic japan
taiwan south korea agreement shionogi take clinic
develop regulatori file commerci mdd japan
taiwan south korea shionogi make up-front payment
million elig develop commerci mileston
million receiv tier royalti sale japan taiwan
south korea averag low rang maintain exclus
right develop commerci outsid japan taiwan south
estim least women us
model moder sever symptom
assum brexanolon launch post decemb pdufa model po
peak ms model price premium brand
antidepress use off-label indic assum row
launch without eu assum market share lost upon launch
easier oral administr efficaci compar risk un-adjust
us sale row model assum po
model potenti launch cost us
base pariti brand antidepress discount half
us price eu row assum peak ms could reach two-third patient
patient moderate-sever symptom risk un-adjust us sale
estim row po risk-
adjust us sale row estim
mdd set model preval unit state patient
seek model primari use ssri treatment-resist
set despit posit compound compani base view
reimburs landscap project potenti approv
model initi net price annual us base pariti
brand antidepress discount half us price eu
japan model potenti penetr mdd patient expect risk
un-adjust ww peak sale reach mdd us
row assum po model us row risk-adjust
peak revenu mdd ww risk-adjust sale
exhibit project brexanolon revenu un-risk adjust
adjust brexanolon probabl success
exhibit project sale mix brexanolon revenu un-risk
adjust adjust brexanolon probabl
expect issu us patent cover composit matter
expir april without extens pend us foreign patent applic cover
use treat variou disord solid form sage-
revenuesmillion usdunadj brexanolon salesunadj revenuesmillion usdrisk-adj brexanolon salesrisk-adj salesbrexanolon po po -brexanolon un risk-adjust revenuestot brexanolon total mddbrexanolon risk-adjust revenuestot brexanolon total mdd outperform
issu patent cover lead product candid brexanolon
iv model loss ip
jeff join ceo year experi
scientif busi side pharmaceut healthcar industri particularli
field join team jeff serv presid
regen medicin divis shire plc previous senior vice presid
research develop shire prior shire serv
execut vice presid chief medic offic
execut vice presid forest laboratori inc senior-level posit
upjohn laboratori jeff found serv ceo
presid sceptor industri serv chairman presid chief
technolog offic earlier career serv independ director
therapeut inc director publish
scientif paper chapter author book scientif articl
abstract receiv numer award
jeff receiv amherst colleg harvard medic school
complet resid psychiatri harvard serv chief resid
psychopharmacolog mclean hospit harvard medic school
steve join steve former practic psychiatrist
previous serv execut director/therapeut area clinic director
inflamm neurosci respiratori divis astrazeneca
pharmaceut astrazeneca also serv chair neurosci safeti
knowledg group time astrazeneca steve serv medic scienc
senior director neurosci establish brand emerg anesthesia group
product team posit increas respons neurosci
discoveri medicin earli late develop group prior join astrazeneca
faculti member psychiatri depart univers pennsylvania
school medicin continu serv adjunct assist professor
psychiatri steve author co-author peer-review public
serv ad hoc review journal neuropsychopharmacolog american
journal medic genet biolog psychiatri
steve receiv univers pennsylvania ph
state univers new york stoni brook complet psychiatri resid
yale-new medic center postdoctor fellowship univers
al join cso year drug discoveri experi
focus primarili neurosci arena recent vice presid
chemistri pharmacokinet scienc lundbeck usa respons
drug discoveri analyt comput pharmacokinet depart
focus synapt transmiss neuroinflamm prior lundbeck al
senior director head neurosci discoveri chemistri depart wyeth
research tenur group success deliv drug
candid clinic develop broad rang neurosci indic al
co-author manuscript abstract co-inventor patent
patent applic
al hold chemistri renssela polytechn institut ph organ
chemistri univers california irvin american chemic societi
postdoctor fellow colorado state univers
kimi join cfo bring financi oper strength
senior manag experi millennium emerg life scienc
compani prior join kimi serv chief oper offic north
america prior held role vice presid
financ cyberkinet neurotechnolog system previous kimi senior
director report analysi millennium pharmaceut
senior manag extern report inc also work busi
assur manag pricewaterhousecoop llp start career chemistry-
relat posit variou boston-bas compani
kimi hold chemistri drew univers
univers earn massachusett
mike join chief busi offic april lead commerci
portfolio program manag medic affair corpor develop
depart previous serv senior vice presid us commerci
led us affili direct gener manag respons sale
market market access patient servic commerci oper mike
tenur held role increas respons includ senior vice
zealand affili vice presid busi plan prior work
bain compani consult special healthcar mike earn
darden graduat school busi administr univers virginia
colleg holi cross
jim doherti ph senior vice presid research
jim join year experi neurosci drug
discoveri develop recent serv director head
neurosci pain innov medicin unit astrazeneca
pharmaceut sodertalj sweden respons lead preclin
research neurolog pain control prior director head
neurosci depart wilmington del
respons lead preclin research psychiatri cognit
experi discoveri translat scienc earli develop sever area
neurosci research includ psychiatri neurolog cognit epilepsi analgesia
jim led multipl team deliv candid compound clinic develop
author peer-review research review articl
jim hold biolog univers delawar ph neurosci
georgetown univers post-doctor fellow emori univers medic
tom join april chief commerci strategi offic prior
tom serv senior vice presid corpor strategi commerci assess
shire plc serv gener manag sever shire psychiatri neurolog
product addit led shire specialti pharmaceut commerci oper
busi inform strateg market function play lead role busi
develop effort prior shire two separ tenur spent year
johnson johnson pharmaceut compani notabl janssen ortho-mcneil
held senior-level role market market research sale sale
manag oper engin employ johnson
johnson presid chief execut offic ranir corpor dental
product compani also corpor offic director execut
vice presid chief oper offic lander co inc healthcare-rel
consum packag good compani previous corpor offic
tom hold civil engin lehigh univers financ
univers notr dame
expect peak sale brexanolon reach ww
brexanolon un-risk-adjust assum
probabl success brexanolon probabl success
project brexanolon potenti approv
expect peak sale mdd reach ww us un-risk-
adjust market share mdd patient initi annual price
us assum probabl success mdd
unrisk-adjust ww sale asset brexanolon risk-adjust
risk-adjust
revenuesmillion usdunadj brexanolon salesunadj revenuesmillion usdrisk-adj brexanolon salesrisk-adj salesbrexanolon po po -brexanolon un risk-adjust revenuestot brexanolon total mddbrexanolon risk-adjust revenuestot brexanolon total mdd outperform
believ near commerci earli commerci biotech compani market
cap work neurosci repres relev
comparison compani rel scarc outlin
compani view compar
purpos valuat look ratio enterpris valu year consensu
revenu revenu note compani approv product
earli commerci significantli de-risk near commerci compani
still subject regulatori approv risk view close
commerci posit studi near-term fda ad pdufa
therefor valuat revenu similar earli
commerci compani exhibit
exhibit near earli commerci late stage neurosci compani
companytickermarket cap consensu revenuesacadia hold compani plc sponsor bioscienc consensu revenuess bubbl correl market cap
valu use dcf analysi assum wacc
residu growth rate due loss ip protect addit pipelin
asset ep respect
expect growth ep cash
balanc
exhibit dcf valuat
yeartermin valu growth valu valu per sharetermin valu growth valu per shareprob success iv brexanoloneprob success outperform
exhibit incom statement forecast
probabilitiy adj product brexanolon revenu total goods- gross oper expensesresearch adjust research develop share-bas compens total share-bas adjust sell gener administr share-bas compens total share-bas total share-bas compens exclud oper oper interest income/expens expens total non-oper income/ expens foreign currenc translat tax incom tax expens benefit tax ratenet basic share outstand share outstand dilut
exhibit balanc sheet forecast
asset cash prepaid expens current market current properti restrict toal liabilitiescurr liabil account accru expens current total current debt net current portion- prefer stock warrant liabil total addit paid-in accumul total stockhold total liabil outperform
exhibit statement forecast
fy incom adjust stock compens premium market amort premium market acquir in-process d- oper asset liabil prepaid expens current account accru expens flow proce sale market purchas properti purchas market incl cash flow proce stock option exercis employe stock payment offer net proce public offer common flow net increas decreas cash begin effect fx equival
discount except per-shar data thousand except per-shar data revenu growth chang work work capit valu growth valu oppenheim valu per sharetermin valu growth rateequ valu per shareprob success iv brexanoloneprob success
risk un-adjust revenu salesbrexanolon salesbrexanolon brexanolon mdd mdd adjust revenu adjustmentsprob brexanolon salesbrexanolon salesbrexanolon brexanolon mdd mdd unadjustedunadj brexanolon adjustedrisk-adj brexanolon therapeut
zulresso brexanolon
probabl success
probabl success
mdd
probabl success
collabor revenu mileston
good
research devleop
adjust research develop non-gaap
share-bas compens
total share-bas compenst
gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compenst
total share-bas compens exclud non-gaap
total non-oper income/ expens
earn tax loss
equival
stock price compani mention report
shionogi co ltd jyen cover
